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Abstract
Background: Pompe disease is a rare, progressive metabolic myopathy. The aim of this study is to investigate the
associations of physical outcomes with patient-reported outcome measures (PROMs) in late-onset Pompe disease.
Methods: We included 121 Dutch adult patients with Pompe disease.
Physical outcomes comprised muscle strength (manual muscle testing using Medical Research Council [MRC]
grading, hand-held dynamometry [HHD]), walking ability (6-min walk test [6MWT]), and pulmonary function (forced
vital capacity [FVC] in upright and supine positions).
PROMs comprised quality of life (Short Form 36 health survey [SF-36]), participation (Rotterdam Handicap Scale
[RHS]) and daily-life activities (Rasch-Built Pompe-Specific Activity [R-PAct] Scale).
Analyses were cross-sectional: the time-point before, and closest to, start of Enzyme Replacement Therapy was
chosen. Associations between PROMs and physical outcomes were investigated using linear regression models.
Results: RHS and R-PAct scores were better in patients with higher FVC supine and upright, HHD, MRC and 6MWT
scores, accounting for the effect of sex, disease duration, use of wheelchair and ventilator support. While the SF-36
Physical Component Summary (PCS) was correlated positively with FVC upright, HHD, MRC and 6MWT scores, there
was no significant relationship between the SF-36 Mental Component Summary (MCS) and any of the physical
outcomes.
Conclusions: Participation, daily-life activities, and the physical component of quality of life of adult Pompe
patients are positively correlated to physical outcomes. This work serves as a first step towards assessing how
changes over time in physical outcomes are related to changes in PROMs, and to define the minimal change in
physical outcomes required to make an important difference for the patient.
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Background
Pompe disease is a rare, progressive metabolic myopathy.
Partial or total deficiency of the enzyme acid α-glucosidase
leads to a build up of lysosomal glycogen, causing cellular
damage in virtually all body tissues, and in particular
muscle [1]. Patients with late-onset Pompe disease present
with a progressive muscle weakness, which leads to limita-
tions in motor function and respiratory difficulties. Since
2006, Enzyme Replacement Therapy (ERT) with recom-
binant human alpha-glucosidase has been available for
Pompe disease.
Many studies have investigated the effects of ERT in
adult patients with Pompe disease. After the initial
placebo-controlled trial [2], studies were observational
and mostly without a control group comparing to the
baseline situation before treatment started [3–8]. A few
studies also compared to patients’ expected disease
course had they remained untreated [9, 10]. Together
these studies have provided evidence of a beneficial ef-
fect of ERT at group level on physical outcomes (motor
performance, muscle strength, pulmonary function), and
survival [11, 12]. At individual patient level, the response
to treatment varied. The improvements in physical out-
comes were found to be greatest in the first 2 to 3 years
after ERT, but also after 5 years of treatment these out-
comes were better at group level than expected without
treatment [10]. Follow-up of 30 patients from the initial
trial showed large variation in the response after 10
years, with 52% having a similar or better distance
walked and/or pulmonary function compared to when
they started treatment [13].
An important question is how patients experience their
disease and the effects of ERT. A few studies have assessed
patient reported outcome measures (PROMs) in Pompe
disease. These have shown that the disease has a large im-
pact on the participation of patients in daily life, and that
the physical domains of their quality of life are affected
but the mental domains less so [2, 14, 15]. With ERT, par-
ticipation stabilised at group level, the physical domains of
quality of life improved initially and then remained stable,
while the mental domains of quality of life did not change
before and during ERT [16].
PROMs and physical outcomes thus both sketch a pic-
ture of a progressive disease and a positive effect of ERT
at group level. However, it is unknown how well the
physical outcome measures reflect what an individual
patient experiences, and whether changes over time in
physical outcomes capture changes in PROMs for an in-
dividual patient. Given that physical outcomes are more
often assessed than PROMs, it would be useful to know
how much benefit a patient experiences (in terms of
their PROMs) from an improvement in a physical out-
come, and how large a change in physical outcomes
needs to be to result in a meaningful improvement in
the experience of a patient. To assess how well these
measures coincide for an individual patient, PROMs and
physical outcomes need to be collected in the same pa-
tients at similar time-points.
Here we report on the first comprehensive study to in-
vestigate the associations of physical outcomes with
PROMs cross-sectionally. Data from the International
Pompe Association (IPA)/Erasmus MC survey [17],
which collects several PROMs in an international group
of patients, was used. For Dutch patients this was linked
to the most commonly reported physical outcomes. We
modelled the relationship between physical outcomes
and PROMs at a specific point in time when the patient
was not yet treated.
Methods
Data collection
This study was performed as part of two prospective ob-
servational cohort studies in Dutch patients with a con-
firmed diagnosis of Pompe disease. The studies are
conducted at the Center for Lysosomal and Metabolic
Diseases, Erasmus MC University Medical Center, Rot-
terdam, the national referral center for Pompe disease in
the Netherlands. Physical outcomes were assessed every
3 to 6 months before and after the start of ERT since
January 2005 [9]. PROMs were collected through ques-
tionnaires, which were mostly sent out through the IPA/
Erasmus MC Pompe survey. This annual survey was sent
out by mail from May 2002 onwards, and since May
2009 also collected through a secure web survey system
[17]. The database for the current study was locked in
December 2018. It included 121 Dutch adult patients.
Both studies were approved by the ethics committee of
the Erasmus MC University Medical Center and written
informed consent was obtained from all participants.
Outcome measures
Clinical outcome measures
Skeletal muscle strength was measured using the Med-
ical Research Council (MRC) grading scale and by hand-
held dynamometry (HHD; Cytec dynamometer, Gro-
ningen, The Netherlands) [18, 19]. The following muscle
groups were tested for both methods: neck extensors,
neck flexors, shoulder abductors, elbow flexors, elbow
extensors, hip flexors, hip abductors, knee flexors, and
knee extensors. In addition, the MRC grade was deter-
mined for the shoulder adductors, shoulder exorotators
and endorotators, hip extensors, and hip adductors. This
was expressed as the percentage of the maximum pos-
sible score for MRC sum scores, and as the percentage
of the median strength of healthy males and females for
HHD sum scores. In the present analysis, no score was
calculated if three or more items were missing. Walking
ability was assessed using the six-minute walk test
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(6MWT) in which the distance walked in 6 min was re-
corded [20]. The results were presented as a percentage
of the predicted normal values [21]. Forced vital capacity
(FVC) was measured in upright seated and supine posi-
tions. Results were expressed as the percentage of the
predicted FVC [22, 23]. The use of wheelchair and venti-
lator support was registered at each visit.
Patient-reported outcome measures (PROMs)
Quality of life was assessed using the Medical Outcome
Study 36-item Short Form Health Survey (SF-36) [24].
Summary scores in two domains were derived: the phys-
ical component summary measure (PCS) and the mental
component summary measure (MCS). Norm-based
scores were calculated using the Dutch 1998 norm-
based scoring, ensuring the comparability of the results
for both versions of the SF-36 [25]. (SF-36 version 1.0
for 2002 to 2009, and afterwards version 2.0).
Participation in daily life activities was assessed using
the Rotterdam Handicap Scale (RHS) [15, 26]. Ability to
carry out daily life activities was assessed by using the
Rasch-Built Pompe-Specific Activity (R-PAct) scale [27].
The RHS is a general measurement scale, which com-
prises 9 items. The scores per item range from 1 (‘unable
to fulfil the task or activity’) to 4 (‘complete fulfilment of
the task or activity’). A score of 0 indicated that the task
or activity could not be applied. The total score is calcu-
lated as the sum of the item scores divided by the number
of applicable items and multiplied by 9. Sum scores were
calculated if at most three items were non-applicable or
missing. The R-PAct scale is designed specifically for
Pompe disease, which consists of 18 items addressing daily
life activities with three response options (0 = unable to
perform; 1 = able to perform, but with difficulty; 2 = able
to perform without difficulty). Only when all items had
been answered, a centile metric score (0–100) was calcu-
lated as described previously [27].
Statistical analysis
Continuous variables are presented as median and range
while categorical variables are presented as frequency
and percentage.
The physical measurements and the PROMs were col-
lected repetitively over time in both cohort studies. Also
before ERT there were usually multiple measurements
available. We selected only those pairs of physical out-
come and PROM that were less than 3 months apart
(and before start of ERT). When multiple pairs were
available for a patient, we chose the pair that was closest
to the start of ERT. The number of patients for each pair
of outcomes are presented in the Supplement, Table 1.
The relationship between each physical outcome and
each patient-reported outcome was investigated using a
linear regression model, which included sex, disease
duration and use of wheelchair and ventilator as poten-
tial confounders. We calculated disease duration as the
difference between the date of symptom onset and the
date the physical outcome was assessed.
The first step to build the model was to investigate
whether the association between physical outcomes and
PROMs is linear or non-linear. We assumed a flexible
non-linear relationship using smoothing spline functions
for the physical measurement variables, natural cubic
splines with up to 2 degrees of freedom. The F-test was
used to investigate which of the models (linear versus
non-linear) was more appropriate.
A problem that arises when comparing the results be-
tween models with different outcomes is that the out-
comes are not measured on the same scale. To
overcome this, we present the standardized regression
coefficients in addition to the original coefficients. Each
variable can be standardized by subtracting its mean
from each of its values and then dividing by the standard
deviation of the variable prior to the regression analysis.
The standardized coefficients can then be interpreted as
the number of standard deviations the dependent out-
come will change if the independent outcome changes
one standard deviation.
The multiple testing problem was addressed by the
Holm method and a significance level of 0.05 was as-
sumed. Models were fitted for each pair of outcome
measures using the statistical program R (version 3.5.1)
(ref: R Core Team (2019). R: A language and environ-
ment for statistical computing. R Foundation for Statis-
tical Computing, Vienna, Austria. URL http://www.R-
project.org/).
Results
Participants
One hundred and twenty-one adult Pompe patients were
included for this study. The inclusion process was as
shown in Fig. 1. There were two reasons for excluding
patients: no PROMs collected before the start of ERT
(n = 10) and no record of date of symptom onset avail-
able (n = 1). For each pair of physical outcome and
PROM that we analyzed, the number of patients avail-
able for analysis was determined by whether these out-
comes were assessed before ERT and whether the two
measurements were within 3 months of each other. The
exact number of patients per analysis can be found in
the Supplement Table 1.
Table 1 shows the characteristics of the study popula-
tion at the time of examination. Participants had a median
age of 53 years (range 23–79) and a median disease dur-
ation of 16 years (range 0.2–50), 53% were women, 45%
were partially or permanently wheelchair dependent, and
26% used mechanical ventilation.
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Associations between physical outcomes and PROMs
First, we assessed whether linear or non-linear models
were needed to describe relationships between the phys-
ical outcomes and PROMs. In most cases, non-linear
models did not provide a better fit of the data, and linear
models were selected. For the relationship between the
MRC and PCS, and the HHD and R-PAct non-linear
models were statistically better (p-values are presented
in the Supplement Table 2). However, on visual inspec-
tion of these two distributions, there is no strong evi-
dence supporting the non-linear models. The
Supplement Fig. 1 displays the fitted results of linear and
non-linear models for both distributions. For simplicity,
the linear models were therefore used.
In the two following sections, we will use two pairs of
outcomes as examples to describe the interpretation of
the results. In the clinical trial on ERT in Pompe disease,
the two key physical outcomes were FVC upright and
6MWT scores. We will describe the positive relation-
ships of FVC upright with RHS, and of 6MWT with R-
Pact below. The results for all models can be found in
the Supplement material Table 3.1–3.20.
FVC upright with RHS
On average across patients, scoring 1 %-point higher on
the FVC upright (presented as percentage of predicted)
corresponded to a 0.147 points higher RHS score (Esti-
mate: 0.147; 95%CI [0.107, 0.186]; p < 0.001), accounting
for sex, disease duration and the use of wheelchair and
ventilator (Supplement Table 3.3).
Dutch patients participating in 
IPA/Erasmus MC Pompe Survey
(n=132)
Study population for analyses
(n=121)
No data before start ERT
(n=10)
Missing important information
(n=1)
Fig. 1 Flowchart of the study population for analyses
Table 1 Characteristics of the study population
Demographic and clinical characteristics Patients (n =
121)
Women: number (%) 64 (53)
Age at examination in years: median (range) 53 (23–79)
Disease durationa at examination in years: median
(range)
16 (0.2–50)
Wheelchairb use at examination: number (%) 54 (45)
Respiratory support at examination: number (%) 32 (26)
Physical outcomes Median (range)
FVC upright (% pred) 77 (10–117)
FVC supine (% pred) 63 (13–107)
HHD sum score (% max) 81 (21–100)
MRC sum score (% max) 85 (39–100)
6MWT (% pred) 67 (6–120)
PROMs Median (range)
SF-36 PCS score (norm-based) 33 (17–63)
SF-36 MCS score (norm-based) 48 (19–72)
RHS score 29 (11–36)
R-PAct score 60 (7–100)
FVC Forced Vital Capacity, HHD Hand-Held Dynamometry, MRC Medical
Research Council, 6MWT Six-Minute Walk Test, SF-36 Short-Form 36 Health
Survey, RHS Rotterdam Handicap Scale, R-Pact Rash-built Pompe-Specific
Activity scale
aduration from symptom onset
bpartial and permanent wheelchair use
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Also wheelchair dependence (Estimate: -4.069; 95%CI
[− 5.599, − 2.539]) was associated with a worse RHS
score: a wheelchair dependent person having a 4.069
point lower RHS score on average. No significant differ-
ence in RHS scores was found among patients of differ-
ent sex, disease duration and the use of ventilation
(Supplement Table 3.3).
Figure 2 (left-hand side) shows the model results for
the relationships between FVC upright and RHS in the
situation where the patient is female, does not use a
wheelchair or respiratory support and has the popula-
tion’s median disease duration of 16 years.
6MWT with R-PAct
A 1 %-point higher 6MWT (also presented as percent-
age of predicted) corresponded, on average, to a 0.348
unit higher R-PAct score (Estimate: 0.348; 95%CI [0.147,
0.549]; p = 0.01), accounting for sex, disease duration
and the use of wheelchair and ventilator (Supplement
Table 3.20).
R-PAct scores were not found to be related to sex, dis-
ease duration and the use of wheelchair and ventilation
(Supplement Table 3.20). Figure 2 (right-hand side) shows
the model results for the relationships between 6MWT
and R-PAct for a female patients with a median disease
duration and no wheelchair or respiratory support.
Strength of associations across models
The aforementioned results provide the interpretation
for the specific associations between one pair of physical
outcome and PROM, using the original regression coef-
ficients. However, to compare the strength of the rela-
tionships across models, we applied standardized
regression coefficients. Please note that these standard-
ized coefficients do not have the same interpretation as
the original coefficients. They do not correspond to the
unit of measurement of the specific outcomes, and can
therefore be compared in size between the different pairs
of outcomes. Figure 3 provides the visualization of the
strength of the associations as a heatmap. Green
indicates a negative association, red positive. The stron-
ger the association, the more intense the color.
A better FVC upright was associated with better PCS
scores (Standardized Estimate: 0.47; CI [0.244, 0.696]),
RHS scores (Standardized Estimate: 0.56; 95%CI [0.41,
0.71]) and R-PAct scores (Standardized Estimate: 0.485;
95%CI [0.304, 0.666]), accounting for the effect of sex,
disease duration and the use of wheelchair and ventila-
tor. Higher FVC supine score was associated with better
RHS (Standardized Estimate: 0.387; 95%CI [0.207,
0.567]) and R-PAct (Standardized Estimate: 0.396; CI
[0.203, 0.588]), accounting for the effect of sex, disease
duration and the use of wheelchair and ventilator. A
borderline significant relationship was found between
the PCS score and FVC supine (p = 0.061, Table 4 in the
supplementary material), and, in general, the standard-
ized coefficients for FVC upright were larger than for
FVC supine.
The MRC score was positively correlated with the
PCS (Standardized Estimate: 0.47; 95%CI [0.254,
0.686]), RHS (Standardized Estimate: 0.423; 95%CI
[0.262, 0.583]) and R-PAct (Standardized Estimate:
0.595; 95%CI [0.426, 0.764]), accounting for the effect
of sex, disease duration and the use of wheelchair
and ventilator. The HHD score was positively corre-
lated with the PCS (Standardized Estimate: 0.323;
95%CI [0.096, 0.55]), RHS (Standardized Estimate:
0.29; 95%CI [0.105, 0.474]) and R-PAct (Standardized
Estimate: 0.386; 95%CI [0.196, 0.577]), accounting for
the effect of sex, disease duration and the use of
wheelchair and ventilator. In comparison, HHD stan-
dardized coefficients were smaller than for MRC.
The 6MWT score was positively associated with the
PCS (Standardized Estimate: 0.584; 95%CI [0.289, 0.878]),
RHS (Standardized Estimate: 0.485; 95%CI [0.232, 0.739])
and R-PAct (Standardized Estimate: 0.495; 95%CI [0.217,
0.773]), accounting for the effect of sex, disease duration
and the use of wheelchair and ventilator.
No significant relationships were found between the
mental component of the SF36 and any of the physical
Fig. 2 Modelled results for the relationship between FVC upright and RHS (left), and 6MWT and R-PAct (right) for female patients with median
disease duration (16 years) and without wheelchair and respiratory support
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outcome measures (p > 0.05, Table 4 in the supplemen-
tary material).
The size of the standardized coefficients can be inter-
preted in terms of standard deviations. In bird-view, the
R-PAct, RHS and PCS would be between 0.3 and 0.6
(rounded) standard deviations higher when a physical
outcome is one standard deviation larger.
Discussion
This is the first study to comprehensively evaluate the
associations of PROMs with physical outcomes in adult
patients with Pompe disease. We show that participation
in, and the ability to perform, daily life activities were
positively correlated with all physical outcomes. Also,
the physical component of the SF-36 (PCS) was posi-
tively correlated with the physical outcome measures,
except that there was only a borderline significant asso-
ciation with FVC supine. No significant relationships
were found between the SF-36 mental scores (MCS) and
any of the physical outcome.
Two earlier studies have looked at associations be-
tween one PROM and one or two physical out-
come(s). The present study on the other hand gives a
comprehensive overview as it includes the most com-
monly assessed PROMs and clinical outcomes. In an
earlier study from our own group we had already re-
ported the positive associations between participation
in daily life (RHS) and the FVC and MRC [28]. Posi-
tive associations of the physical component of quality
of life (PCS) with both FVC upright and the MRC
were also described in an international meta-analysis
[29]. This study corroborates the present results, as
the individual level data used in the international
study did not include the Dutch patients included in
the present study.
The absence of a relationship between the physical
outcomes and MCS may suggest that the differences
in physical outcomes were not associated with
changes in mental health. Also in previous studies of
Pompe patients, mental health scores were found to
be within the normal range and no improvement was
seen with ERT [14, 16]. An explanation might be that
late-onset Pompe disease is a chronic disease and af-
fects patients progressively. As a result, patients may
adapt to their situation over time and adjust their ex-
pectations [30], explaining the normal mental health
scores. This phenomenon is called response shift, and
is a recognized issue in studies of health-related qual-
ity of life amongst chronic patients, including cancer
patients [31, 32].
For each pair of physical outcome and PROM, the
number of patients available for analysis was different.
There were slightly more pairs of PROMs with up-
right FVC than with supine FVC, as more severely af-
fected patients with Pompe disease may not be able
to perform lung function testing in supine position,
while they can still be tested in upright position. Pos-
sibly, the slightly lower number of measurements ex-
plains the borderline p-value that was observed for
the association between FVC supine and PCS. The
fact that more severely affected patients may be ex-
cluded from supine FVC testing also means that for
Fig. 3 Associations between physical outcomes and PROMs. Heatmap visualizing the strength of the associations between physical outcomes
and PROMs. Each cell represents one linear regression model. The standardized regression coefficient are displayed to ensure the comparability of
different models. Green indicates a negative association, red a positive one. The stronger the association, the more intense the color. Statistically
significant coefficients are indicated by *. Detailed results including estimates for sex, disease duration and the use of wheelchair and ventilator
can be found in the supplemental material
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PROMs paired with FVC supine the range of mea-
sured outcome values (both PROM and FVC) may be
narrower than for the pairing with FVC upright. To-
gether with the somewhat lower number of measure-
ments, this might explain why the association of
PROMs with supine FVC was less strong than with
upright FVC.
A similar difference was found for muscle strength,
where the strength of associations with PROMs were
found to be larger for MRC scores compared to HHD
scores. Here, the reason could be that more muscle
groups were measured using MRC grading scale. An-
other reason could be there are more missing values for
the HHD scores (as shown in Table A1). The number of
patients for whom 6MWT data were available before
ERT was smaller than all other outcomes. While reasons
for this include that severely affected patients may not
be able to perform this test, the main reason for this was
that the test was not yet a standard outcome measure in
the first years of this study.
Our analyses are based on 121 adult Pompe pa-
tients, which is a very large sample size for this rare
disease. However, for statistical analyses this number
was still limited and meant that the number of con-
founders corrected for was the maximum possible.
Another concern may be that the number of pairs
available for each analyses may not differ at random
but are driven by disease severity. This is true for
the smaller number of supine FVC measurements
compared to upright, and partly for the 6MWT, and
the interpretation of these results should be limited
to exclude the most severe patients. However, the
differences between upright and supine measure-
ments available were not large, and the fewer
6MWT assessments available was mostly random
(calendar time).
Clinical implications
The positive associations observed suggest that physical
outcomes reflect at least part of what the patient experi-
ences. The next question to ask is how much PROMs
improve when a patient’s physical outcome improves.
For example, if the patient can walk 10 m extra on the
6MWT, can he/she do the grocery shopping alone? Ul-
timately, we would like to be able to give guidance on
how much a physical outcomes needs to improve to
make an important difference for the patient with
Pompe disease.
Conclusions
Here we confirm that for adult Pompe patients who are
not yet treated with ERT, there is a relationship between
physical outcomes and PROMs at the individual patient
level, except for the mental aspect of quality of life. This
study serves as a first step towards disentangling the re-
lations between physical outcomes and PROMs over
time and towards providing guidance on how much of a
change is meaningful for the patient. The next steps in
this research will therefore be to study the associations
between these sets of outcomes over time and with ERT
and to define the minimal clinically important difference
(MCID) under ERT for Pompe disease that can be used
for clinical decision making.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13023-020-01469-7.
Additional file 1.
Acknowledgements
We thank all patients for participating in the study. We are also grateful to
the referring physicians, research nurses, and Dutch patient representatives
for their contributions to the organizational part of the study.
Authors’ contributions
Data acquisition: MY, LH, NvdB. Study concept and design: MK, NvdB, AvdP.
Statistical analysis: MY, EA, DR, AL. Analysis and interpretation of data: MY, EA,
DR, MK, NvdB, AvdP, AL. Original draft preparation: MY Critical revision of
manuscript for intellectual content: EA, DR, MK, NvdB, AvdP Obtained funding:
MK, NvdB, AvdP. The author(s) read and approved the final manuscript.
Funding
This work was supported by Sanofi-Genzyme.
Availability of data and materials
The data that support the findings of this study are not publicly available to
protect patient privacy. Please contact the author (NvdB) for further
information.
Ethics approval and consent to participate
All studies in this paper were approved by the ethics committee of the
Erasmus MC University Medical Center and have therefore been performed
in accordance with the ethical standards laid down in the 1964 Declaration
of Helsinki and its later amendments. Written informed consent was
obtained from all participants prior to their inclusion.
Consent for publication
Not applicable.
Competing interests
A. van der Ploeg received funding for research, clinical trials and as an
advisor from various industries working on ERT or next-generation therapies
in the field of Pompe disease, other lysosomal storage diseases, and neuro-
muscular disorders under agreements with Erasmus MC University Medical
Center and the relevant industry. N. van der Beek received funding for re-
search and as advisor from various industries working on ERT or next-
generation therapies in the field of Pompe disease under agreements with
Erasmus MC University Medical Center and the relevant industry. The other
authors declare that they have no conflict of interest.
Author details
1Department of Biostatistics, Erasmus MC University Medical Center,
Rotterdam, The Netherlands. 2Department of Pediatrics, Center for Lysosomal
and Metabolic Diseases, Erasmus MC University Medical Center, Rotterdam,
The Netherlands. 3Department of Neurology, Center for Lysosomal and
Metabolic Diseases, Erasmus MC University Medical Center, Rotterdam, The
Netherlands.
Yuan et al. Orphanet Journal of Rare Diseases          (2020) 15:232 Page 7 of 8
Received: 4 May 2020 Accepted: 21 July 2020
References
1. Hirschhorn R, Reuser AJ. Glycogen storage disease type II: acid alpha-
glucosidase (acid maltase) deficiency. In: Scriver CR, Beaudet AL, Valle D, Sly
W, Childs B, Kinzler KW, et al., editors. The metabolic and molecular bases of
inherited disease. 8th ed. New York: McGraw-Hill; 2001. p. 3389–420.
2. van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld
GJ, et al. A randomized study of alglucosidase alfa in late-onset Pompe’s
disease. N Engl J Med. 2010;362(15):1396–406.
3. Anderson LJ, Henley W, Wyatt KM, Nikolaou V, Waldek S, Hughes DA, et al.
Effectiveness of enzyme replacement therapy in adults with late-onset
Pompe disease: results from the NCS-LSD cohort study. J Inherit Metab Dis.
2014;37(6):945–52.
4. Angelini C, Semplicini C, Ravaglia S, Bembi B, Servidei S, Pegoraro E, et al.
Observational clinical study in juvenile-adult glycogenosis type 2 patients
undergoing enzyme replacement therapy for up to 4 years. J Neurol. 2012;
259(5):952–8.
5. Bembi B, Pisa FE, Confalonieri M, Ciana G, Fiumara A, Parini R, et al. Long-
term observational, non-randomized study of enzyme replacement therapy
in late-onset glycogenosis type II. J Inherit Metab Dis. 2010;33(6):727–35.
6. Regnery C, Kornblum C, Hanisch F, Vielhaber S, Strigl-Pill N, Grunert B, et al.
36 months observational clinical study of 38 adult Pompe disease patients
under alglucosidase alfa enzyme replacement therapy. J Inherit Metab Dis.
2012;35(5):837–45.
7. Strothotte S, Strigl-Pill N, Grunert B, Kornblum C, Eger K, Wessig C, et al.
Enzyme replacement therapy with alglucosidase alfa in 44 patients with
late-onset glycogen storage disease type 2: 12-month results of an
observational clinical trial. J Neurol. 2010;257(1):91–7.
8. Van der Ploeg AT, Barohn R, Carlson L, Charrow J, Clemens PR, Hopkin RJ,
et al. Open-label extension study following the late-onset treatment study
(LOTS) of alglucosidase alfa. Mol Genet Metab. 2012;107(3):456–61.
9. de Vries JM, van der Beek NA, Hop WC, Karstens FP, Wokke JH, de Visser M,
et al. Effect of enzyme therapy and prognostic factors in 69 adults with Pompe
disease: an open-label single-center study. Orphanet J Rare Dis. 2012;7:73.
10. Kuperus E, Kruijshaar ME, Wens SCA, de Vries JM, Favejee MM, van der
Meijden JC, et al. Long-term benefit of enzyme replacement therapy in
Pompe disease: a 5-year prospective study. Neurology. 2017;89(23):2365–73.
11. Gungor D, Kruijshaar ME, Plug I, D'Agostino RB, Hagemans ML, van Doorn
PA, et al. Impact of enzyme replacement therapy on survival in adults with
Pompe disease: results from a prospective international observational study.
Orphanet J Rare Dis. 2013;8:49.
12. van der Ploeg AT, Kruijshaar ME, Toscano A, Laforet P, Angelini C, Lachmann
RH, et al. European consensus for starting and stopping enzyme
replacement therapy in adult patients with Pompe disease: a 10-year
experience. Eur J Neurol. 2017;24(6):768–e31.
13. Harlaar L, Hogrel JY, Perniconi B, Kruijshaar ME, Rizopoulos D, Taouagh N,
et al. Large variation in effects during 10 years of enzyme therapy in adults
with Pompe disease. Neurology. 2019;93(19):e1756–e67.
14. Hagemans ML, Janssens AC, Winkel LP, Sieradzan KA, Reuser AJ, Van Doorn
PA, et al. Late-onset Pompe disease primarily affects quality of life in
physical health domains. Neurology. 2004;63(9):1688–92.
15. Hagemans ML, Laforet P, Hop WJ, Merkies IS, Van Doorn PA, Reuser AJ, et al.
Impact of late-onset Pompe disease on participation in daily life activities:
evaluation of the Rotterdam handicap scale. Neuromuscul Disord. 2007;
17(7):537–43.
16. Güngör D, Kruijshaar ME, Plug I, Rizopoulos D, Kanters TA, Wens SCA, et al.
Quality of life and participation in daily life of adults with Pompe disease
receiving enzyme replacement therapy: 10 years of international follow-up.
J Inherit Metab Dis. 2016;39(2):253–60.
17. van der Meijden JC, Gungor D, Kruijshaar ME, Muir AD, Broekgaarden HA,
van der Ploeg AT. Ten years of the international Pompe survey: patient
reported outcomes as a reliable tool for studying treated and untreated
children and adults with non-classic Pompe disease. J Inherit Metab Dis.
2015;38(3):495–503.
18. Medical Research Council. Aids to examination of the peripheral nervous
system. Memorandum no. 45. London: Office HMsS; 1976.
19. van der Ploeg RJ, Fidler V, Oosterhuis HJ. Hand-held myometry: reference
values. J Neurol Neurosurg Psychiatry. 1991;54(3):244–7.
20. American Thoracic Society Committee on Proficiency Standards for Clinical
Pulmonary Function Laboratories. ATS statement: guidelines for the six-
minute walk test. Am J Respir Crit Care Med. 2002;166(1):111–7.
21. Enright PL, Sherrill DL. Reference equations for the six-minute walk in
healthy adults. Am J Respir Crit Care Med. 1998;158(5 Pt 1):1384–7.
22. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC.
Lung volumes and forced ventilatory flows. Report working party
standardization of lung function tests, European Community for steel and
coal. Official statement of the European Respiratory Society. Eur Respir J
Suppl. 1993;16:5–40.
23. American Thoracic Society/European Respiratory Society. ATS/ERS statement
on respiratory muscle testing. Am J Respir Crit Care Med. 2002;166(4):518–624.
24. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36).
I. Conceptual framework and item selection. Med Care. 1992;30(6):473–83.
25. Aaronson NK, Muller M, Cohen PD, Essink-Bot ML, Fekkes M, Sanderman R,
et al. Translation, validation, and norming of the Dutch language version of
the SF-36 health survey in community and chronic disease populations. J
Clin Epidemiol. 1998;51(11):1055–68.
26. Merkies IS, Schmitz PI, Van Der Meche FG, Samijn JP, Van Doorn PA.
Psychometric evaluation of a new handicap scale in immune-mediated
polyneuropathies. Muscle Nerve. 2002;25(3):370–7.
27. van der Beek NA, Hagemans ML, van der Ploeg AT, van Doorn PA, Merkies
IS. The Rasch-built Pompe-specific activity (R-PAct) scale. Neuromuscul
Disord. 2013;23(3):256–64.
28. Kanters TA, Redekop K, Rutten-Van Mölken MPMH, Kruijshaar ME, Güngör D,
et al. A conceptual disease model for adult Pompe disease. Orphanet J Rare
Dis. 2015;10:112.
29. Berger KI, Kanters S, Jansen JP, Stewart A, Sparks S, An Haack K, et al. Forced
vital capacity and cross-domain late-onset Pompe disease outcomes: an
individual patient-level data meta-analysis. J Neurol. 2019;266(9):2312–21.
30. Kempen GI, Ormel J, Brilman EI, Relyveld J. Adaptive responses among
Dutch elderly: the impact of eight chronic medical conditions on health-
related quality of life. Am J Public Health. 1997;87(1):38–44.
31. Ilie G, Bradfield J, Moodie L, Lawen T, Ilie A, Lawen Z, et al. The role of
response-shift in studies assessing quality of life outcomes among Cancer
patients: a systematic review. Front Oncol. 2019;9:783.
32. Schwartz CE, Sprangers MA. Methodological approaches for assessing
response shift in longitudinal health-related quality-of-life research. Soc Sci
Med. 1999;48(11):1531–48.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Yuan et al. Orphanet Journal of Rare Diseases          (2020) 15:232 Page 8 of 8
